Executive Management
Carl Spana, Ph.D., President and Chief Executive Officer
Dr. Spana, co-founder of Palatin, has served as president and chief executive officer since 2000. He has been a director of Palatin since 1996 and has been a director of Palatin’s wholly-owned subsidiary, RhoMed Incorporated, since 1995. From 1996 to 2000, Dr. Spana served as an executive vice president and chief technical officer of Palatin.
From 1993 to 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From 1991 to 1993, Dr. Spana was a research associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly traded medical technology company.
Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
Stephen T. Wills, C.P.A., M.S.T., Chief Financial Officer and Executive Vice President - Operations
Mr. Wills joined Palatin as vice president and chief financial officer in 1997. He brings a depth of financial experience in public accounting and healthcare to the company.
From 1991 to 2000, Mr. Wills served as the president and chief operating officer of Golomb, Wills and Company, P.C., a public accounting firm. During that time, from 1997 to 2000, he was also the vice president and chief financial officer of Derma Sciences, Inc., a publicly held company providing wound and skin care products. Mr. Wills is currently a director of Derma Sciences.
Mr. Wills, a certified public accountant, earned his B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.
Trevor Hallam, Ph.D., Executive Vice President of Research & Development
Dr. Hallam joined Palatin in May, 2005 as executive vice president of research & development. He possesses over 20 years of drug discovery and development experience within the pharmaceutical industry.
From 1996 to 2005, Dr. Hallam held key senior management leadership positions within AstraZeneca R&D, including vice president of biologics based out of the UK, vice president of respiratory and inflammation research based in Sweden and vice president of medical affairs within the US. During this time, Dr. Hallam developed and implemented programs to broaden the firm’s portfolio of products, established strategic partner relationships and defined new discovery strategies. From 1985 to 1995, Dr. Hallam served at progressively senior management positions within Smith Kline & French Research, Glaxo Group Research and Roche Research. His accomplishments include development of numerous drug candidates for a variety of indications, including asthma, rheumatoid and osteo-arthritis, multiple sclerosis and transplant rejection.
Dr. Hallam joined the pharmaceutical industry after a post-doctoral fellowship at the Physiological Laboratory, University of Cambridge, UK. He earned his Ph.D. in biochemistry from the University of London and his B.Sc. from the University of Leeds.
